This study aimed to close an analytical gap by improving a VAMS-based strategy [27] to allow assessing adherence to all classes of AHD listed in the current guidelines for hypertension treatment which include thiazide diuretics, calcium-channel blockers (CCBs), angiotensin-converting-enzyme (ACE) inhibitors, or angiotensin II receptor blockers (ARBs), and spironolactone in case of resistant hypertension [6, 28, 29]. This evidence concerns the gene ACE and Hypertension.